Beta Bionics Q3 2026 net loss widens 71% year over year to $24.35 million; Q3 2026 net sales rise 30% to $35.51 million year over year
Bitget2026/10/27 20:03- Beta Bionics’ third-quarter 2026 net loss widened 71% year over year to $24.35 million.
- Net sales rose 30% year over year to $35.5 million, while PBP channel net sales more than doubled to $13.6 million.
- FDA-cleared Mint is expected to launch commercially across the U.S. in the first quarter of 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Orient Precision Industries Holds Extraordinary Shareholders Meeting
Crypto prices
More
